Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100477 · ClinicalTrials.gov registry record · Phase 2
Use of Topotecan in Patients With Refractory Acute Leukemia
A Phase 2 study of Leukemia and Non-Hodgkin's Lymphoma, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00100477 is a Phase 2 study of Leukemia and Non-Hodgkin's Lymphoma that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 10 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00100477, a Phase 2 study of Leukemia and Non-Hodgkin's Lymphoma, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
Conditions Studied
Interventions
- DRUG Etoposide
- DRUG Topotecan
- DRUG Mitozantrone
Study Locations (1)
Florida
- North Florida/South Georgia Veterans Health System - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1998-08 |
| Est. Completion | 2001-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100477
The ClinicalTrials.gov registry entry for NCT00100477 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (98% lower). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Etoposide is the first listed.
NCT00100477 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00100477 about?
NCT00100477 is a clinical study titled "Use of Topotecan in Patients With Refractory Acute Leukemia". The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone an...
What is the current status of trial NCT00100477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 1998-08. Estimated completion is 2001-06.
What conditions does trial NCT00100477 study?
This clinical trial studies the following conditions: Leukemia, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00100477?
The interventions under investigation include: Etoposide (DRUG), Topotecan (DRUG), Mitozantrone (DRUG).
Who is sponsoring clinical trial NCT00100477?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00100477 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.